Dual-antigen recognition iPSC-derived CAR-T cells for B-cell malignancies: establishment of a COVID-19 vaccine synergy strategy - PubMed
6 hours ago
- #CAR-T
- #iPSC-derived T-cells
- #vaccine synergy
- Dual-antigen recognition iPSC-derived CAR-T cells target both CD19 and COVID-19 spike protein for B-cell malignancies.
- The study introduces a vaccine synergy strategy to enhance CAR-T cell persistence via TCR restimulation.
- 1919-CARrejTs show superior cytotoxicity, proliferative capacity, and reduced exhaustion markers compared to conventional CD19-CAR-T cells.
- TCR-mediated stimulation by spike protein peptide enhances the proliferative capacity of 1919-CARrejTs in an HLA-dependent manner.
- The findings suggest a promising treatment approach for B-cell malignancies by combining iPSC rejuvenation and dual-antigen recognition.